EUVIMEDEUVIMED entdecken
Open Access

Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control

Siri Lillegraven, Nina Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Daniel H Solomon, Désirée van der Heijde, Espen A Haavardsholm

JAMA · 28.03.2023 · 329 (12) · 1024

DOI: 10.1001/jama.2023.0492 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 28.03.2023. Verfasst von Siri Lillegraven und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid, Withholding Treatment. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This open-label randomized clinical trial assessed the 12-month risk of disease activity flares after discontinuation of conventional synthetic DMARDs (csDMARDs) compared with continuing half-dose csDMARDs in adult Norwegian patients with rheumatoid arthritis and excellent disease control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsArthritis, RheumatoidWithholding TreatmentHumansBiological ProductsDrug Therapy, CombinationMethotrexateTreatment Outcome

Substanzen

Antirheumatic AgentsBiological ProductsMethotrexate

Autor:innen und Institutionen

  • Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.
  • Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Leiden University Medical Centre, Department of Rheumatology, Leiden, the Netherlands.

Zitieren

APA

Lillegraven, S., Paulshus Sundlisæter, N., Aga, A. B., Sexton, J., Solomon, D. H., van der Heijde, D., & Haavardsholm, E. A. (2023). Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control. JAMA, 329(12), 1024. https://doi.org/10.1001/jama.2023.0492

Vancouver

Lillegraven S, Paulshus Sundlisæter N, Aga AB, Sexton J, Solomon DH, van der Heijde D, et al. Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control. JAMA. 2023;329(12):1024. doi:10.1001/jama.2023.0492

BibTeX
@article{Lillegraven2023,
  author = {Lillegraven, Siri and Paulshus Sundlisæter, Nina and Aga, Anna-Birgitte and Sexton, Joseph and Solomon, Daniel H and van der Heijde, Désirée and Haavardsholm, Espen A},
  title = {Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control},
  journal = {JAMA},
  year = {2023},
  volume = {329},
  number = {12},
  pages = {1024},
  doi = {10.1001/jama.2023.0492}
}
Kostenlos starten →